Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis
Open accessThe DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index; 74 of the 161 sources its claims cite were checked for support.
Abstract
Background: Immune checkpoint inhibitors (ICI) are a keystone in advanced hepatocellular carcinoma (aHCC) therapy. However, preclinical evidence suggests that mice with pure metabolic dysfunction-associated steatohepatitis (MASH)-related HCCs may not benefit from ICIs. This has tremendous implications for both therapy selection and future drug development. Summary: Viral and MASH-HCCs differ in molecular pathogenesis and immune microenvironment. Preclinical evidence has shown impaired immune surveillance and ICI-induced auto-aggressive T cells in pure MASH-HCC. Phase 3 clinical trials and meta-analyses have conflicting outcomes. For single-ICI regimens with anti-programmed-death 1/L1 (anti-PD1/L1), there was no apparent difference in the overall survival for patients with non-viral HCCs in the CheckMate-459, IMbrave150, COSMIC-312, and KEYNOTE-240 trials for ICI over tyrosine-kinase inhibitors or placebo, while patients with viral hepatitis seemed to have benefited more. Meanwhile, comparable outcomes were seen for patients with viral and non-viral HCCs in the HIMALAYA, RATIONALE-301, LEAP-002, and CARES-310 trials. There was no consistent difference in outcomes between patients with HBV or HCV-HCCs. For dual-ICI regimens with anti-PD1/L1 and anti-cytotoxic T-lymphocyte associated protein-4 (anti-CTLA-4), the HIMALAYA and CheckMate-9DW trials showed similar efficacy for ICI combinations across all etiologies. Important caveats in interpreting current evidence exist. All trial data are from unplanned subgroup analyses only, limiting the level of clinical evidence available. "Non-viral HCCs" are also a heterogenous entity, the composition of which varies from trial to trial. Fundamentally, defining HCC etiologies, especially in mutually exclusive terms, is challenging: Occult hepatitis B infections are inconsistently tested and reported; hence, viral HCCs may be underreported. HCCs are often multifactorial, with steatosis frequently co-existing and interacting with viral hepatitis, creating difficulty in translating findings from pure MASH-HCC mouse models. Key Messages: Current evidence is insufficient to support individualizing aHCC treatment based on etiology. Preclinical evidence for a lesser benefit with ICIs in MASH-HCCs exists, while data from clinical trials are mixed but limited. Major gaps in knowledge remain, and further studies are required to clarify this important subject.
Overview
CoChat Summary
## TL;DR
This narrative review concludes that current evidence is insufficient to support tailoring unresectable/advanced HCC treatment by etiology, even though preclinical studies suggest ICIs may be less effective or potentially harmful in pure MASH-HCC. Across phase 3 trials and meta-analyses, results are mixed, with more consistent benefit for viral HCCs in some single-ICI studies and preserved efficacy of dual-ICI regimens across etiologies.
## Key findings
- Preclinical studies in NASH/MASH models found that anti-PD1 therapy could worsen NASH and increase HCC incidence, and that mice with pure MASH-HCC may not benefit from ICIs.
- In CheckMate-459, OS HRs for nivolumab vs sorafenib were 0.77 for HBV-HCC, 0.71 for HCV-HCC, and 0.95 for non-viral HCC; ORRs were 19%, 17%, and 12%, respectively, versus 7–8% with sorafenib.
- In KEYNOTE-240, pembrolizumab vs placebo showed a numerically greater OS benefit in HBV-HCC (HR 0.57) than in non-viral HCC (HR 0.88); the authors note only 15.5% of patients had HCV-HCC.
- Meta-analyses were inconsistent: one pooled analysis of 3 ICI trials (n = 1,656) found better OS in viral than non-viral HCCs (HR 0.64 vs 0.92, p for heterogeneity = 0.0259), while a later meta-analysis found OS benefit in both viral and non-viral HCCs (HR 0.79 overall; HBV 0.70, HCV 0.78, non-viral 0.87).
## Methods
- Narrative review of preclinical, translational, and clinical literature on ICI use in HCC across etiologies, focusing on viral hepatitis and MASH-related HCC.
- Literature searches were conducted in electronic databases such as PubMed, restricted to English-language publications, with additional citation chasing from retrieved papers.
- The paper synthesizes phase 3 trial subgroup analyses and meta-analyses; no primary patient-level dataset or original statistical analysis was performed by the authors.
## Limitations
- The paper states that most clinical evidence comes from unplanned subgroup analyses that are not powered for formal comparison, and meta-analyses are based on trial-level rather than individual patient data.
- The paper states that etiology definitions are inconsistent across trials, including variable testing for occult HBV and lack of biopsy-based confirmation of MASH; “non-viral” groups are heterogeneous.
- Evident from the text: the review’s clinical conclusions are constrained by incomplete reporting of baseline characteristics, toxicities, ORR/DCR, survival curves, and post-progression therapy by etiology, so findings remain hypothesis-generating rather than definitive.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
28 Valid · 31 Not valid · 65 Not checked · 60 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“However, in a more recent meta-analysis conducted by Meyer et al. [48] which included other studies mentioned above, a significant OS advantage for both patients with viral and non-viral HCCs was found (HR 0.79, p < 0.001).”
§ Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis > Clinical Evidence: A Critical Appraisal > Summary of Current Evidence
What the sources say
- Disputedcites [48] sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says this meta-analysis used only objective response rate because too few studies reported overall survival (OS) by viral status. Its Results report an ORR comparison, not the claimed significant OS advantage or HR 0.79. The paper therefore explicitly rules out the OS meta-analysis attributed to it. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Patients with HBV-HCCs had the largest predicted benefit (HR 0.70, p < 0.001), followed by patients with HCV-HCCs (HR 0.78, p = 0.04) and patients with non-viral HCCs (HR 0.87, p = 0.02).”
§ Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis > Clinical Evidence: A Critical Appraisal > Summary of Current Evidence
What the sources say
- Disputedcites [48] sourceExperimental — accuracy not yet measured
The Results section reports odds ratios for objective response rate, not the claimed HCV-HCC hazard ratio of 0.78 (p = 0.04). The Discussion states that objective response rate was the only reliable endpoint for this meta-analysis because too few studies reported survival outcomes by viral etiology. Page numbers are unavailable in our copy. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Further stratification of non-viral etiologies was only done in COSMIC-312 and LEAP-002”
§ Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis > Major Limitations in Available Clinical Evidence
What the sources say
- Partly supportedcites [35] sourceExperimental — accuracy not yet measured
The Methods passage (page not available in our copy) says COSMIC-312 randomisation was stratified by disease aetiology. It does not establish further stratification within non-viral aetiologies or the claim that only COSMIC-312 and LEAP-002 did this; searches for “non-viral” and LEAP-002 found no supporting passage. (LLM, conf=0.72)
- Disputedcites [36] sourceExperimental — accuracy not yet measured
The Statistical Analysis section (page unavailable) lists viral aetiology as a yes-or-no subgroup but does not subdivide non-viral aetiologies; it also says that no additional subgroups were included post hoc. That is contrary to the claim that LEAP-002 further stratified non-viral aetiologies. This paper does not establish which other trials did so. (LLM, conf=0.78)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“preclinical evidence suggests that mice with pure metabolic dysfunction-associated steatohepatitis (MASH)-related HCCs may not benefit from ICIs.”
- Also stated in: § Molecular and Microenvironment Differences of Viral and MASH-Related HCCs · plain
“Finally, when mice with NASH-HCC were given anti-PD1, no response was obtained despite expanded CD8+PD1+CXCR6+, TOX+, and TNF+ T cells [22].”
§ Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis > Abstract > Background
What the sources say
- Supportedcites [22] source
In “Hepatic CD8+PD1+ T cells increase in NASH,” mice with diet-induced NASH–HCC showed no regression of existing tumours after anti-PD1 or anti-PDL1 treatment. The paper contrasts this with tumour regression in non-NASH mouse models, supporting the qualified claim that mice with MASH-related HCC may not benefit from ICIs. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Molecular and Microenvironment Differences of Viral and MASH-Related HCCs · plain
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“In RATIONALE-301, the HR for patients with HBV, HCV, and non-viral HCCs were 0.91 (0.73–1.14), 0.64 (0.38–1.08), and 0.78 (0.55–1.12) in the tislelizumab arm [29].”
§ Etiology-Based Treatment for Unresectable/Advanced Hepatocellular Carcinoma: Focus on Viral Hepatitis and Metabolic Dysfunction-Associated Steatohepatitis > Clinical Evidence: A Critical Appraisal > Summary of Current Evidence
What the sources say
- Could not verifycites [29] sourceExperimental — accuracy not yet measured
The Methods (Statistical Analysis; page unavailable) identify HCV etiology as an analysis factor, and the Discussion (page unavailable) mentions OS subgroup analyses. Searches for the HCV subgroup HR and its reported confidence interval found neither 0.64 nor 0.38–1.08 in our copy, so the specific estimate cannot be verified. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
137 more claims · 40 with their cited sources checked
Create a free account to see all 184 claims and to verify the 29 references still open.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 13
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · cited 2×
“As an example, the proportion of patients classified to have non-viral HCC ranged from less than 20% in CARES-310, 30.5% in IM-Brave150 to up to 45% in Checkmate-459 [27, 37, 62].”
InfluentialLlovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497 · cited 2×
“Only IMBrave150 and COSMIC-312 re-ported the median OS in patients with non-viral HCCs [31, 35], but the outcomes for sorafenib were remarkable (18 and 20 months) compared to patients with viral HCCs in the same trials (12–14 months) or to historical data of sorafenib in unselected HCC [32, 33].”
InfluentialMechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354 · cited 1×
“MASH promotes HCC through lipotoxicity, causing oxidative and endoplasmic reticulum stress, which induces inflammation and cell damage [14, 15] reactivation of molecular pathways such as Notch, Hedgehog, and YAP-TAZ in hepatocytes leads to inflammation, cell proliferation, and cancer [16].”
The Global Epidemic of the Metabolic Syndrome
Saklayen, M. G. (2018) · Current Hypertension Reports · doi:10.1007/s11906-018-0812-z · Cited by 3,990 · cited 1×
“The global epidemic of metabolic syndrome has contributed significantly to the increasing prevalence of MAFLD [6] which has increased over 50% in the Asia-Pacific region over the past two decades and affects 30–40% of the global population [3, 4, 7].”
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383 · cited 1×
“1), the “non-viral” subgroups probably consist of different proportions of HCCs due to each etiology across different trials, as the above example has shown [63–65].”
A multisociety Delphi consensus statement on new fatty liver disease nomenclature
Rinella, M. E., Lazarus, J. V., Ratziu, V., Francque, S. M., Sanyal, A. J., Kanwal, F., Romero, D., Abdelmalek, M. F., Anstee, Q. M., Arab, J. P., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.06.003 · Cited by 3,100 · cited 1×
“…dysfunction-associated steatotic liver disease (MASLD), defined as hepatic steatosis in the setting of at least one cardiometabolic risk factor without other causes of steatosis, can progress to MASH, characterized by histological features of lobular inflammation and hepatocellular ballooning [5].”
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490 · cited 2×
“HCV-HCCs demonstrate increased TERT promoter mutation and CDKN2A promotor silencing, which leads to downregulation of tumor suppressor p16 [12].”
Estes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,399
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
Global burden of primary liver cancer in 2020 and predictions to 2040
Rumgay, H., Arnold, M., Ferlay, J., Lesi, O., Cabasag, C. J., Vignat, J., Laversanne, M., McGlynn, K. A., & Soerjomataram, I. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.021 · Cited by 2,197
Global Burden of Disease Liver Cancer Collaboration, Akinyemiju, T., Abera, S., Ahmed, M., Alam, N., Alemayohu, M. A., Allen, C., Al-Raddadi, R., Alvis-Guzman, N., Amoako, Y., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3055 · Cited by 1,987
Alcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Gao, B., & Bataller, R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.09.002 · Cited by 1,963 · cited 1×
“Aside from co-existent MAFLD and viral hepatitis, the effects of alcohol on steatosis, accelerated cirrhosis, and hepatocarcinogenesis in patients with viral hepatitis are well established [95, 96].”
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874 · cited 1×
“Combined PD1 and CTLA-4 blockade creates distinct biological effects compared to blocking PD1 alone, such as the expansion of memory T cells and differential levels of various plasma chemokines [39, 40].”
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855 · cited 2×
“Corresponding, the burden of MASH-related HCCs has been increasing rapidly [8].”
Finn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.01307 · Cited by 1,789 · cited 2×
“In KEYNOTE-240, OS benefits seem numerically greater in patients with HBV-HCC (HR 0.57 [0.35–0.94]) treated with pembrolizumab compared to placebo, while the HR of patients with non-viral HCCs was 0.88 (0.64–1.20) [46].”
InfluentialSelf-citationSingh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748 · cited 1×
“Steatosis itself is insufficient to cause HCC without inflammation, and only around 20% of patients with MASLD have MASH [70].”
Cheng, A.-L., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Lim, H. Y., Kudo, M., Breder, V., Merle, P., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.11.030 · Cited by 1,743 · cited 3×
“Only IMBrave150 and COSMIC-312 re-ported the median OS in patients with non-viral HCCs [31, 35], but the outcomes for sorafenib were remarkable (18 and 20 months) compared to patients with viral HCCs in the same trials (12–14 months) or to historical data of sorafenib in unselected HCC [32, 33].”
InfluentialSenescence surveillance of pre-malignant hepatocytes limits liver cancer development
Kang, T.-W., Yevsa, T., Woller, N., Hoenicke, L., Wuestefeld, T., Dauch, D., Hohmeyer, A., Gereke, M., Rudalska, R., Potapova, A., et al. (2011) · Nature · doi:10.1038/nature10599 · Cited by 1,621 · cited 1×
“CD4+ T cells play the center role in immune surveillance and clearance of premalignant hepatocytes [26].”
Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Abou-Alfa, G. K., Lau, G., Kudo, M., Chan, S. L., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Van Dao, T., De Toni, E. N., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2100070 · Cited by 1,576 · cited 1×
“For example, HBV DNA was tested in all patients in HIMALAYA, and HBV infection was defined by positive HBsAg, detectable HBV DNA or anti-HBc [69].”
Self-citationRandomized controlled trial of screening for hepatocellular carcinoma
Zhang, B.-H., Yang, B.-H., & Tang, Z.-Y. (2004) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0552-0 · Cited by 1,496 · cited 1×
“HCC screening is known to reduce overall disease-related mortality mainly effected through detecting HCCs at an earlier stage to allow for more curative resections [54, 58].”
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03362-0 · Cited by 1,294 · cited 4×
“Importantly, in a series of landmark pre-clinical studies using mouse models, immune checkpoint blockade seemed to instead exacerbate NASH via CD8+ T cell-mediated mechanisms in livers without HCCs, without corresponding anti-tumor activity in NASH-related HCC [21, 22].”
InfluentialYau, T., Park, J.-W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Harding, J. J., Merle, P., Rosmorduc, O., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00604-5 · Cited by 1,106 · cited 5×
“…the benefits seem more noticeable in patients with viral HCCs. Pre-specified subgroup analyses for overall survival (OS) in patients with HBV or HCV-HCCs showed HRs of 0.77 (95% CI 0.56–1.05) and 0.71 (0.49–1.01), respectively, while that of patients with non-viral HCCs was 0.95 (0.74–1.22) [27].”
InfluentialSelf-citationCellular senescence drives age-dependent hepatic steatosis
Ogrodnik, M., Miwa, S., Tchkonia, T., Tiniakos, D., Wilson, C. L., Lahat, A., Day, C. P., Burt, A., Palmer, A., Anstee, Q. M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15691 · Cited by 1,044 · cited 1×
“HCV also exacerbates lipotoxicity by increasing liver ROS levels through effects of HCV core proteins and mitochondrial dysfunction [77], as well as causing hepatocytes to become senescent and accumulate fat [78].”
Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance
Marusyk, A., Janiszewska, M., & Polyak, K. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.007 · Cited by 1,009 · cited 1×
“A larger overall tumor bulk is associated with higher intra-tumoral genomic heterogeneity [60], which is a major driver for therapy resistance due to a larger plethora of potentially resistant clones [61].”
Rushing, B. R., & Selim, M. I. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.11.047 · Cited by 989 · cited 1×
“1), the “non-viral” subgroups probably consist of different proportions of HCCs due to each etiology across different trials, as the above example has shown [63–65].”
EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma
Sangro, B., Argemi, J., Ronot, M., Paradis, V., Meyer, T., Mazzaferro, V., Jepsen, P., Golfieri, R., Galle, P., Dawson, L., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.028 · Cited by 985
Okuda, M., Li, K., Beard, M. R., Showalter, L. A., Scholle, F., Lemon, S. M., & Weinman, S. A. (2002) · Gastroenterology · doi:10.1053/gast.2002.30983 · Cited by 926 · cited 1×
“HCV also exacerbates lipotoxicity by increasing liver ROS levels through effects of HCV core proteins and mitochondrial dysfunction [77], as well as causing hepatocytes to become senescent and accumulate fat [78].”
Singal, A. G., Pillai, A., & Tiro, J. (2014) · PLoS Medicine · doi:10.1371/journal.pmed.1001624 · Cited by 817 · cited 2×
“Furthermore, as countries where viral hepatitis infections are endemic have instituted large-scale screening programs, increasingly more viral HCCs have been screen-detected [54, 55].”
Younossi, Z. M., Otgonsuren, M., Henry, L., Venkatesan, C., Mishra, A., Erario, M., & Hunt, S. (2015) · Hepatology · doi:10.1002/hep.28123 · Cited by 802 · cited 1×
“Indeed, major prognostic factors may not have been balanced between subgroups of patients with viral and non-viral related HCCs. Patients with MAFLD/ MASH-related HCCs are known to be older and with more cardiovascular comorbidities compared to those with viral hepatitis [53].”
Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity
Ringel, A. E., Drijvers, J. M., Baker, G. J., Catozzi, A., García-Cañaveras, J. C., Gassaway, B. M., Miller, B. C., Juneja, V. R., Nguyen, T. H., Joshi, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.11.009 · Cited by 780 · cited 1×
“Lastly, both HCV and MASH promote an immune tolerant environment for hepatocarcinogenesis by causing CD8+ T cells and CD4+ T-cell dysfunction [23, 81, 82], as well as the expansion of Tregs [24, 83].”
NAFLD causes selective CD4+ T lymphocyte loss and promotes hepatocarcinogenesis
Ma, C., Kesarwala, A. H., Eggert, T., Medina-Echeverz, J., Kleiner, D. E., Jin, P., Stroncek, D. F., Terabe, M., Kapoor, V., ElGindi, M., et al. (2016) · Nature · doi:10.1038/nature16969 · Cited by 766 · cited 2×
“Lastly, both HCV and MASH promote an immune tolerant environment for hepatocarcinogenesis by causing CD8+ T cells and CD4+ T-cell dysfunction [23, 81, 82], as well as the expansion of Tregs [24, 83].”
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00961-3 · Cited by 746 · cited 2×
“3, 4) [37].”
InfluentialEvolving synergistic combinations of targeted immunotherapies to combat cancer
Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Gracia, J. L. P., & Haanen, J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3973 · Cited by 637 · cited 1×
“The CTLA-4 pathway affects the priming and proliferation phases of T cells, while the PD1 pathway mainly affects the effector phase [38].”
Piscaglia, F., Svegliati‐Baroni, G., Barchetti, A., Pecorelli, A., Marinelli, S., Tiribelli, C., Bellentani, S., & on behalf of the HCC‐NAFLD Italian Study Group (2016) · Hepatology · doi:10.1002/hep.28368 · Cited by 604 · cited 2×
“In fact, MAFLD-related HCCs are often larger in extent at diagnosis compared to viral HCCs [57].”
Update of the statements on biology and clinical impact of occult hepatitis B virus infection
Raimondo, G., Locarnini, S., Pollicino, T., Levrero, M., Zoulim, F., Lok, A. S., Allain, J.-P., Berg, T., Bertoletti, A., Brunetto, M. R., et al. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.034 · Cited by 572 · cited 1×
“In fact, up to 20% of OBIs may be negative for both HBsAg and hepatitis B core antibody (anti-HBc) with existing assays [67, 68].”
Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors
Huang, D. Q., Mathurin, P., Cortez-Pinto, H., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00688-6 · Cited by 553
Kelley, R. K., Rimassa, L., Cheng, A.-L., Kaseb, A., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00326-6 · Cited by 535 · cited 2×
“COSMIC-312 is, uniquely, the only ICI trial to further stratify non-viral causes and describe outcomes specifically for patients with MASH-HCC in a pre-specified manner [34, 35].”
Self-citationAuto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH
Dudek, M., Pfister, D., Donakonda, S., Filpe, P., Schneider, A., Laschinger, M., Hartmann, D., Hüser, N., Meiser, P., Bayerl, F., et al. (2021) · Nature · doi:10.1038/s41586-021-03233-8 · Cited by 518 · cited 3×
“Notably, these T cells were also found in liver biopsy specimens of patients with NASH, suggesting potential translational implications for these preclinical findings [21].”
Llovet, J. M., Kudo, M., Merle, P., Meyer, T., Qin, S., Ikeda, M., Xu, R., Edeline, J., Ryoo, B.-Y., Ren, Z., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00469-2 · Cited by 469
Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
Das, R., Verma, R., Sznol, M., Boddupalli, C. S., Gettinger, S. N., Kluger, H., Callahan, M., Wolchok, J. D., Halaban, R., Dhodapkar, M. V., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401686 · Cited by 461 · cited 1×
“Combined PD1 and CTLA-4 blockade creates distinct biological effects compared to blocking PD1 alone, such as the expansion of memory T cells and differential levels of various plasma chemokines [39, 40].”
Wang, H., Zhang, H., Wang, Y., Brown, Z. J., Xia, Y., Huang, Z., Shen, C., Hu, Z., Beane, J., Ansa-Addo, E. A., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.07.032 · Cited by 398 · cited 2×
“In addition, neutrophil extracellular traps, which are abundant in livers affected by NASH, facilitates mitochondrial oxidative phosphorylation and, thus, differentiation of naïve CD4+ T cells into Tregs, which in turn impairs immunosurveillance of premalignant hepatocytes [24].”
Yau, T., Galle, P. R., Decaens, T., Sangro, B., Qin, S., da Fonseca, L. G., Karachiwala, H., Blanc, J.-F., Park, J.-W., Gane, E., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00403-9 · Cited by 390
Self-citationSangro, B., Chan, S. L., Kelley, R. K., Lau, G., Kudo, M., Sukeepaisarnjaroen, W., Yarchoan, M., De Toni, E. N., Furuse, J., Kang, Y. K., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.02.005 · Cited by 365 · cited 3×
“In the single agent durvalumab arm of HIMALAYA, the HR for OS in patients with HBV, HCV, and non-viral HCCs were 0.81 (0.62–1.07), 1.00 (0.73–1.37), and 0.81 (0.64–1.04), respectively [28].”
InfluentialSelf-citationLim, C. J., Lee, Y. H., Pan, L., Lai, L., Chua, C., Wasser, M., Lim, T. K. H., Yeong, J., Toh, H. C., Lee, S. Y., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316510 · Cited by 357 · cited 2×
“…regulatory T cells (Tregs) and resident CD8+ memory T cells (Trm), which have contradicting functions and effects on prognosis, are upregulated in HBV-related HCCs compared to non-viral HCCs, while Tim3+CD8+ T cells and CD244+ natural killer cells are preferentially enriched in the latter [18].”
Self-citationNonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354 · cited 1×
“MASH promotes HCC through lipotoxicity, causing oxidative and endoplasmic reticulum stress, which induces inflammation and cell damage [14, 15] reactivation of molecular pathways such as Notch, Hedgehog, and YAP-TAZ in hepatocytes leads to inflammation, cell proliferation, and cancer [16].”
Kudo, M., Ren, Z., Guo, Y., Han, G., Lin, H., Zheng, J., Ogasawara, S., Kim, J. H., Zhao, H., Li, C., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02575-3 · Cited by 342
Sangro, B., Kudo, M., Erinjeri, J. P., Qin, S., Ren, Z., Chan, S. L., Arai, Y., Heo, J., Mai, A., Escobar, J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02551-0 · Cited by 333 · cited 2×
“All three trials (LEAP-012 with pembrolizumab-lenvatinib, EMERALD-1 with durvalumab-bevacizumab and TALENTACE with atezolizumab-bevacizumab) have demonstrated PFS benefit without mature OS outcomes [50–52].”
InfluentialSvegliati-Baroni, G., Ridolfi, F., Di Sario, A., Casini, A., Marucci, L., Gaggiotti, G., Orlandoni, P., Macarri, G., Perego, L., Benedetti, A., et al. (1999) · Hepatology · doi:10.1002/hep.510290632 · Cited by 320 · cited 1×
“Meanwhile, metabolic dysfunction worsens the pathogenic effects of HCV. Hyperinsulinemia exacerbates HCV-initiated fibrosis by stimulating insulin-receptor expressing myofibroblasts to cause fibroblast proliferation and collagen secretion [79].”
Kleiner, D. E., & Makhlouf, H. R. (2016) · Clinics in Liver Disease · doi:10.1016/j.cld.2015.10.011 · Cited by 303
Nakamoto, N., Kaplan, D. E., Coleclough, J., Li, Y., Valiga, M. E., Kaminski, M., Shaked, A., Olthoff, K., Gostick, E., Price, D. A., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.033 · Cited by 299 · cited 1×
“Similarly, HCV-HCC exhibits a significant presence of exhausted CD8+ T cells expressing high levels of PD1 [19].”
Qin, S., Kudo, M., Meyer, T., Bai, Y., Guo, Y., Meng, Z., Satoh, T., Marino, D., Assenat, E., Li, S., et al. (2023) · JAMA Oncology · doi:10.1001/jamaoncol.2023.4003 · Cited by 265
Kim, H.-D., Song, G.-W., Park, S., Jung, M. K., Kim, M. H., Kang, H. J., Yoo, C., Yi, K., Kim, K. H., Eo, S., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.08.030 · Cited by 254 · cited 1×
“Anti-PD1 treatment can reactivate PD1+ cytotoxic CD8+ T cells while also attenuating the immunosuppressive functions of PD1+ Treg [18, 20], underscoring the therapeutic relevance of targeting this crucial pathway in viral HCCs.”
Haber, P. K., Puigvehí, M., Castet, F., Lourdusamy, V., Montal, R., Tabrizian, P., Buckstein, M., Kim, E., Villanueva, A., Schwartz, M., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.06.008 · Cited by 248
Pinyol, R., Torrecilla, S., Wang, H., Montironi, C., Piqué-Gili, M., Torres-Martin, M., Wei-Qiang, L., Willoughby, C. E., Ramadori, P., Andreu-Oller, C., et al. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.04.049 · Cited by 247 · cited 1×
“In addition to other typical mutations present in viral HCCs such as TERT, CTNNB1, and TP53, MASH-HCC has higher mutation rates in ACVR2A, a potential tumor suppressor gene, compared to HCCs of other etiologies [17].”
The role of telomeres and telomerase in cirrhosis and liver cancer
Nault, J.-C., Ningarhari, M., Rebouissou, S., & Zucman-Rossi, J. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0165-3 · Cited by 239 · cited 1×
“HBV is capable of hepatocarcinogenesis via insertional mutagenesis within the TERT promoter, resulting in telomerase activation and subsequent hepatocyte transformation [11].”
Machado, M. V., Oliveira, A. G., & Cortez‐Pinto, H. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2011.06801.x · Cited by 233 · cited 1×
“Steatosis is reported in around 30% of patients with HBV, similar to the general population and lower than in patients with HCV [84].”
Liver cancer in 2021: Global Burden of Disease study
Tan, E. Y., Danpanichkul, P., Yong, J. N., Yu, Z., Tan, D. J. H., Lim, W. H., Koh, B., Lim, R. Y. Z., Tham, E. K. J., Mitra, K., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.10.031 · Cited by 232 · cited 1×
“Indeed, although anti-viral therapies have reduced the incidence of viral HCCs, MASH-related HCCs have surged in many parts of the world including the Americas, Eastern Mediterranean, and Southeast Asia [8, 9].”
Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma
Hoshida, Y., Fuchs, B. C., Bardeesy, N., Baumert, T. F., & Chung, R. T. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.07.010 · Cited by 230 · cited 1×
“Conversely, the HCV RNA virus is incapable of integrating into the host genome but induces chronic hepatic inflammation leading to oxidative stress, fibrogenesis, genetic instability, and DNA damage [13].”
Pinato, D. J., Murray, S. M., Forner, A., Kaneko, T., Fessas, P., Toniutto, P., Mínguez, B., Cacciato, V., Avellini, C., Diaz, A., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003311 · Cited by 228 · cited 1×
“This may result in a different tumor and immune microenvironment as TACE is a known inducer of immunogenic cell death [59].”
Mak, L.-Y., Wong, D. K.-H., Pollicino, T., Raimondo, G., Hollinger, F. B., & Yuen, M.-F. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.05.042 · Cited by 223
Self-citationXue, R., Li, R., Guo, H., Guo, L., Su, Z., Ni, X., Qi, L., Zhang, T., Li, Q., Zhang, Z., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.033 · Cited by 214 · cited 1×
“A larger overall tumor bulk is associated with higher intra-tumoral genomic heterogeneity [60], which is a major driver for therapy resistance due to a larger plethora of potentially resistant clones [61].”
Hippo signalling in the liver: role in development, regeneration and disease
Russell, J. O., & Camargo, F. D. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00571-w · Cited by 207 · cited 1×
“MASH promotes HCC through lipotoxicity, causing oxidative and endoplasmic reticulum stress, which induces inflammation and cell damage [14, 15] reactivation of molecular pathways such as Notch, Hedgehog, and YAP-TAZ in hepatocytes leads to inflammation, cell proliferation, and cancer [16].”
Vinciguerra, M., Sgroi, A., Veyrat-Durebex, C., Rubbia-Brandt, L., Buhler, L. H., & Foti, M. (2009) · Hepatology · doi:10.1002/hep.22737 · Cited by 198
Mak, L.-Y., Liu, K., Chirapongsathorn, S., Yew, K. C., Tamaki, N., Rajaram, R. B., Panlilio, M. T., Lui, R., Lee, H. W., Lai, J. C.-T., et al. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00967-4 · Cited by 182
Self-citationLin, C.-W., Lin, C.-C., Mo, L.-R., Chang, C.-Y., Perng, D.-S., Hsu, C.-C., Lo, G.-H., Chen, Y.-S., Yen, Y.-C., Hu, J.-T., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2012.11.045 · Cited by 174 · cited 1×
“Aside from co-existent MAFLD and viral hepatitis, the effects of alcohol on steatosis, accelerated cirrhosis, and hepatocarcinogenesis in patients with viral hepatitis are well established [95, 96].”
Abnormalities of lipid metabolism in hepatitis C virus infection
Negro, F. (2010) · Gut · doi:10.1136/gut.2009.192732 · Cited by 162 · cited 1×
“Most patients with HCV are overweight, and 40–80% have steatosis, which confers worse outcomes compared to HCV alone [75].”
Mak, L.-Y., Hui, R. W.-H., Fung, J., Liu, F., Wong, D. K.-H., Cheung, K.-S., Yuen, M.-F., & Seto, W.-K. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.05.040 · Cited by 152
Self-citationWong, J. S. L., Kwok, G. G. W., Tang, V., Li, B. C. W., Leung, R., Chiu, J., Ma, K. W., She, W. H., Tsang, J., Lo, C. M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001945 · Cited by 142 · cited 1×
“In fact, we and subsequently other groups have shown that combined blockade has activity in aHCC post-progression on single agent anti-PD1/L1, suggesting a possible distinct clinical effect as well [41–43].”
Self-citationHui, R. W. H., Seto, W. ‐., Cheung, K. ‐., Mak, L. ‐., Liu, K. S. H., Fung, J., Wong, D. K. ‐., Lai, C. ‐., & Yuen, M. ‐. (2018) · Journal of Viral Hepatitis · doi:10.1111/jvh.12766 · Cited by 128 · cited 1×
“Meanwhile, whether HBV leads to increased steatosis remains controversial: HBV viral load is observed to be inversely correlated to steatosis [93], but HBV has also been implicated in promoting steatosis via induction of IL-13, TGF-B1, myofibroblasts, and JAK/STAT pathways [74] and through inducing…”
Self-citationDiamond, D. L., Jacobs, J. M., Paeper, B., Proll, S. C., Gritsenko, M. A., Carithers, R. L., Larson, A. M., Yeh, M. M., Camp, D. G., Smith, R. D., et al. (2007) · Hepatology · doi:10.1002/hep.21751 · Cited by 114
Yau, T., Kaseb, A., Cheng, A.-L., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., Verset, G., et al. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00454-5 · Cited by 97
Self-citationLanghans, B., Nischalke, H. D., Krämer, B., Hausen, A., Dold, L., van Heteren, P., Hüneburg, R., Nattermann, J., Strassburg, C. P., & Spengler, U. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.12.019 · Cited by 96 · cited 1×
“Lastly, both HCV and MASH promote an immune tolerant environment for hepatocarcinogenesis by causing CD8+ T cells and CD4+ T-cell dysfunction [23, 81, 82], as well as the expansion of Tregs [24, 83].”
Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis
Im, Y. R., Jagdish, R., Leith, D., Kim, J. U., Yoshida, K., Majid, A., Ge, Y., Ndow, G., Shimakawa, Y., & Lemoine, M. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00201-1 · Cited by 92 · cited 1×
“In fact, up to 20% of OBIs may be negative for both HBsAg and hepatitis B core antibody (anti-HBc) with existing assays [67, 68].”
Meyer, T., Galani, S., Lopes, A., & Vogel, A. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.012 · Cited by 82 · cited 1×
“However, in a more recent meta-analysis conducted by Meyer et al. [48] which included other studies mentioned above, a significant OS advantage for both patients with viral and non-viral HCCs was found (HR 0.79, p < 0.001).”
InfluentialRational HCC screening approaches for patients with NAFLD
Singal, A. G., & El-Serag, H. B. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.08.028 · Cited by 80
Wong, Y. J., Nguyen, V. H., Yang, H.-I., Li, J., Le, M. H., Wu, W.-J., Han, N. X., Fong, K. Y., Chen, E., Wong, C., et al. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0004 · Cited by 77
Self-citationHBx-Induced Hepatic Steatosis and Apoptosis Are Regulated by TNFR1- and NF-κB-Dependent Pathways
Kim, J. Y., Song, E. H., Lee, H. J., Oh, Y. K., Choi, K.-H., Yu, D.-Y., Park, S. I., Seong, J.-K., & Kim, W.-H. (2010) · Journal of Molecular Biology · doi:10.1016/j.jmb.2010.02.016 · Cited by 71 · cited 1×
“…to be inversely correlated to steatosis [93], but HBV has also been implicated in promoting steatosis via induction of IL-13, TGF-B1, myofibroblasts, and JAK/STAT pathways [74] and through inducing mitochondrial dysfunction and peroxisome proliferator-activated receptors by the HBx protein [94].”
NAFLD and HBV interplay - related mechanisms underlying liver disease progression
Tourkochristou, E., Assimakopoulos, S. F., Thomopoulos, K., Marangos, M., & Triantos, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.965548 · Cited by 70 · cited 3×
“5) [73, 74].”
HCV-Specific T Cell Responses During and After Chronic HCV Infection
Luxenburger, H., Neumann-Haefelin, C., Thimme, R., & Boettler, T. (2018) · Viruses · doi:10.3390/v10110645 · Cited by 64 · cited 1×
“Lastly, both HCV and MASH promote an immune tolerant environment for hepatocarcinogenesis by causing CD8+ T cells and CD4+ T-cell dysfunction [23, 81, 82], as well as the expansion of Tregs [24, 83].”
Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions
Leslie, J., Geh, D., Elsharkawy, A. M., Mann, D. A., & Vacca, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.01.029 · Cited by 61 · cited 1×
“5) [73, 74].”
Mak, L.-Y., Hui, R. W.-H., Fung, J., Liu, F., Wong, D. K.-H., Li, B., Cheung, K.-S., Yuen, M.-F., & Seto, W.-K. (2021) · Hepatology International · doi:10.1007/s12072-021-10218-2 · Cited by 58 · cited 1×
“Clinically, steatosis assessed by transient elastography is associated with a 3-fold increase in HBsAg clearance rates, lower incidence of HCC [85–87], but higher risk of fibrosis progression [88].”
Self-citationZhang, R.-N., Pan, Q., Zhang, Z., Cao, H.-X., Shen, F., & Fan, J.-G. (2015) · Hepatitis Monthly · doi:10.5812/hepatmon.15(5)2015.27909 · Cited by 56 · cited 1×
“Immune alterations and metabolic stress related to MASLD, such as toll-like-receptor-4 activation, may enhance anti-viral response and attenuate HBV-related liver disease progression [74, 89].”
Roessler, D., Öcal, O., Philipp, A. B., Markwardt, D., Munker, S., Mayerle, J. V., Jochheim, L. S., Hammer, K., Lange, C. M., Geier, A., et al. (2022) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-022-04206-8 · Cited by 56 · cited 1×
“In fact, we and subsequently other groups have shown that combined blockade has activity in aHCC post-progression on single agent anti-PD1/L1, suggesting a possible distinct clinical effect as well [41–43].”
Espinoza, M., Muquith, M., Lim, M., Zhu, H., Singal, A. G., & Hsiehchen, D. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.042 · Cited by 55 · cited 1×
“Post hoc analysis showed no significant difference in OS, PFS, and ORR for patients with NAFLD, HCV, HBV, and alcoholic liver disease in the atezolizumab-bevacizumab arm, and between NAFLD and HBV or HCV patients specifically [30].”
Ding, Z., Dong, Z., Chen, Z., Hong, J., Yan, L., Li, H., Yao, S., Yan, Y., Yang, Y., Yang, C., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.733530 · Cited by 47 · cited 1×
“A meta-analysis of eight studies involving 1,520 patients by Ding et al. [49] also did not demonstrate a significant difference in ORR across patients with viral and non-viral HCCs (OR 1.03, p for heterogeneity 0.152), or between patients with HBV and HCV-HCCs (OR 0.74, p for heterogeneity 0.374).”
InfluentialDong, J., Han, G., Ogasawara, S., Liu, R., Gu, S., Liu, F., Zhao, M., Hu, H., Liu, Z., Lin, K., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.05.542 · Cited by 47
Synergism in actions of HBV with aflatoxin in cancer development
Jin, J., Kouznetsova, V. L., Kesari, S., & Tsigelny, I. F. (2023) · Toxicology · doi:10.1016/j.tox.2023.153652 · Cited by 43 · cited 1×
“Aflatoxin also synergistically effects HCC development with viral hepatitis through activation of hepatitis B viral proteins such as HBx and other pathways [97].”
The Impact of National Surveillance for Liver Cancer: Results from Real-World Setting in Korea
Kwon, J. W., Tchoe, H. J., Lee, J., Suh, J. K., Lee, J.-H., & Shin, S. (2020) · Gut and Liver · doi:10.5009/gnl18522 · Cited by 27 · cited 1×
“Furthermore, as countries where viral hepatitis infections are endemic have instituted large-scale screening programs, increasingly more viral HCCs have been screen-detected [54, 55].”
Cheu, J. W., & Wong, C. C. (2024) · Hepatology Communications · doi:10.1097/hc9.0000000000000516 · Cited by 24
Self-citationOsmani, Z., Brouwer, W. P., Grashof, D. G. B., Lim, Y., Doukas, M., Janssen, H. L. A., van de Werken, H. J. G., & Boonstra, A. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.10.032 · Cited by 14 · cited 1×
“…shown to have significantly reduced interferon gene signature and pathway activity, as well as macrophage gene signatures, compared to HBV or MASH alone, with uncertain effects due to the diverse roles interferons and immune cells play and the complex liver and systemic immune environment [91, 92].”
Yendewa, G. A., Elangovan, A., Olasehinde, T., Mulindwa, F., Cater, M. G., Salata, R. A., & Jacobson, J. M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1566925 · Cited by 6 · cited 1×
“Clinically, steatosis assessed by transient elastography is associated with a 3-fold increase in HBsAg clearance rates, lower incidence of HCC [85–87], but higher risk of fibrosis progression [88].”
Cheon, J., Kang, B., Jung, S., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.2023.41.4_suppl.554 · Cited by 3
Does MASH comorbidity in CHB truly suppress immune function?
Wei, Z., Shan, D., & Liang, C. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.11.002 · Cited by 2 · cited 1×
“…shown to have significantly reduced interferon gene signature and pathway activity, as well as macrophage gene signatures, compared to HBV or MASH alone, with uncertain effects due to the diverse roles interferons and immune cells play and the complex liver and systemic immune environment [91, 92].”
Cited by
HBV Integration in Clinical Management of Hepatocellular Carcinoma by Liquid Biopsy
Lyu, X., Chan, Z., & Ho, D. W.-H. (2026) · Oncology · doi:10.1159/000551214
“Notably, HBV-associated HCC patients had a better outcome of immune checkpoint inhibitor therapy [112, 113].”
Light across the Pacific Ocean: An Asian perspective on BEACON-HCC
Yau, T. W. C., Yuen, M.-F., & Cheung, T.-T. (2026) · Hepatology · doi:10.1097/hep.0000000000001857
Self-citation
Metadata
- Authors
- Sun, F. S. K., Wong, J. S. L., Mak, L.-Y., Wong, C. C.-L., Chew, V., Li, B. C. W., Leung, R., Cheung, T. T., & Yau, T.
- Affiliations
- Queen Mary Hospital (CN)
- University of Hong Kong (HK)
- SingHealth (SG)
- Corresponding author
- Yau, Thomas
- Venue
- Liver Cancer
- Publisher
- S. Karger AG
- Published
- 2025-09-19
- Volume
- 15
- Issue
- 3
- Pages
- 480-496
- ISSN
- 1664-5553 (ISSN-L)
- 2235-1795
- PMC
- PMC13286557
- OpenAlex
- W7082294778
- Semantic Scholar
- 627873f4f828a9e83ea081d33a6db7d96b6b7fde
- Cited by
- 3
- References
- 96
- Citations by year
- 2026: 3
- FWCI
- 0.29
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Liver Cancer (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
- Keywords
- advanced hepatocellular carcinoma, immune checkpoint inhibitors, nonalcoholic steatohepatitis, viral hepatitis, hepatitis B, hepatitis C, cancer etiology, PD-1/PD-L1 blockade, CTLA-4 blockade, immune microenvironment, immune surveillance, subgroup analysis, tyrosine kinase inhibitors, steatosis, treatment selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.